Suppr超能文献

尿中丁丙诺啡、去甲丁丙诺啡和纳洛酮浓度及其比值:综述及潜在临床意义。

Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications.

机构信息

Aspenti Health, South Burlington, VT (JSW, SF-F); University of Vermont Medical Center, Robert Larner School of Medicine, Department of Pathology and Laboratory Medicine (JSW); University of Vermont, Mathematics and Statistics (GSW) and University of Vermont College of Medicine, Family Medicine and Psychiatry, Burlington, VT (JB).

出版信息

J Addict Med. 2020 Dec;14(6):e344-e349. doi: 10.1097/ADM.0000000000000676.

Abstract

OBJECTIVES

Treatment with medications for opioid use disorder such as buprenorphine improves patient morbidity and mortality as well as treatment adherence, an important component of patient care. Buprenorphine is combined with naloxone to reduce misuse; and, when taken sublingually, naloxone is poorly absorbed. Urine testing for buprenorphine is a common way to monitor adherence. Some patients who want to appear adherent may directly tamper with their urine by adding buprenorphine to their urine to allow for the detection without ingestion. Practitioners may rely upon the concentration of buprenorphine and the metabolite, norbuprenorphine, and utilize the ratio of metabolite to parent compound (norbuprenorphine:buprenorphine - N:B ratio) to discern possible evidence of tampering; however, there remains debate as to what specific ratio may signify this practice. Testing for naloxone may also help determine if urine tampering occurred as only low naloxone concentrations are found in the urine when taken by a sublingual route.

METHODS

To determine a reliable N:B ratio that may be used to identify possible urine tampering by adding parent drug directly to urine, we examined 136,605 urine samples for quantitative concentrations of buprenorphine and norbuprenorphine by LC-MS/MS performed at a commercial laboratory. After identifying abnormal ratios (<0.02), we then compared them with naloxone concentrations and specimen validity testing, other markers that may coincide with specimen tampering of this type.

RESULTS

Correlating urinary buprenorphine and norbuprenorphine concentrations, we found 2 distinct patient populations, which could be distinguished by N:B ratios ranging from 0.01 to 0.2. In addition, while the distribution of urine naloxone concentrations itself did not demonstrate distinct populations, naloxone was able to further flag potential tampered specimens when combined with N:B ratios. Abnormal specimen validity testing was additionally found more commonly in cases with N:B ratios <0.02.

CONCLUSIONS

This comprehensive study compared N:B ratios with naloxone concentrations and specimen validity testing. This study suggests that a N:B ratio of <0.02 in concert with high naloxone concentrations (>1000 ng/ml) can help to identify potential cases of tampered urine samples.

摘要

目的

阿片类药物使用障碍治疗药物(如丁丙诺啡)可改善患者的发病率和死亡率以及治疗依从性,这是患者护理的重要组成部分。丁丙诺啡与纳洛酮联合使用可减少滥用;当舌下给药时,纳洛酮吸收不良。尿液检测丁丙诺啡是监测依从性的常用方法。一些想要表现出依从性的患者可能会直接篡改尿液,将丁丙诺啡添加到尿液中,以便在不摄入的情况下进行检测。从业者可能依赖于丁丙诺啡及其代谢物去甲丁丙诺啡的浓度,并利用代谢物与母体化合物的比值(去甲丁丙诺啡:丁丙诺啡-N:B 比值)来辨别可能存在的篡改证据;然而,对于什么特定的比值可能表示这种做法,仍存在争议。检测纳洛酮也有助于确定尿液是否被篡改,因为只有当纳洛酮通过舌下途径给药时,尿液中才会发现低浓度的纳洛酮。

方法

为了确定一个可靠的 N:B 比值,该比值可用于识别直接向尿液中添加母体药物可能导致的尿液篡改,我们在商业实验室通过 LC-MS/MS 对 136605 个尿液样本进行了定量检测丁丙诺啡和去甲丁丙诺啡的浓度。在确定异常比值(<0.02)后,我们将其与纳洛酮浓度和标本有效性检测进行了比较,这些检测结果可能与这种类型的标本篡改相符。

结果

通过对尿液丁丙诺啡和去甲丁丙诺啡浓度进行相关性分析,我们发现了 2 个不同的患者群体,可以通过 N:B 比值为 0.01 到 0.2 来区分。此外,虽然尿液纳洛酮浓度本身的分布没有显示出明显的群体,但当与 N:B 比值结合使用时,纳洛酮能够进一步标记潜在的篡改标本。异常标本有效性检测也更多地出现在 N:B 比值<0.02 的情况下。

结论

本综合研究比较了 N:B 比值与纳洛酮浓度和标本有效性检测。本研究表明,当 N:B 比值<0.02 且纳洛酮浓度较高(>1000ng/ml)时,有助于识别潜在的篡改尿液样本。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验